Difference between revisions of "BioNTech"
(Importing from WP and expanding) |
(Sahin quote + mark as shallow) |
||
| (13 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
| + | <div style="border:2px solid #3333ff; background-color:#ccccff; padding:0.4em 0.5em; margin:auto; width:40%; text-align:center;"> | ||
| + | [[File:too shallow.png|left|72px]]'''This page is too shallow.'''<br/> {{{1|It needs work to add a [[deep political]] perspective.}}}</div> | ||
{{Group | {{Group | ||
|wikipedia=https://en.wikipedia.org/wiki/BioNTech | |wikipedia=https://en.wikipedia.org/wiki/BioNTech | ||
| + | |constitutes=Big Pharma | ||
|image=BioNTech.jpg | |image=BioNTech.jpg | ||
| + | |description=German biotechnology company worth billions after being selected producer of a [[COVID jab]]. | ||
|image_width=240px | |image_width=240px | ||
|founders=Christoph Huber, Ugur Sahin, Özlem Türeci | |founders=Christoph Huber, Ugur Sahin, Özlem Türeci | ||
}} | }} | ||
| − | '''BioNTech''' is a [[Germany|German]] biotechnology company | + | '''BioNTech''' is a [[Germany|German]] biotechnology company. As of 2024, the company does not have any other product but the [[Pfizer–BioNTech COVID-19 vaccine|Pfizer–BioNTech COVID-19 "vaccine"]] (BNT162b2). The company received 55 million USD in [[2019]] from the [[Bill & Melinda Gates-Foundation]].<ref>http://archive.today/2021.12.30-185241/https://www.wiwo.de/unternehmen/dienstleister/biontech-einstieg-mit-50-millionen-warum-bill-gates-auf-biontech-aus-mainz-setzt/24981368.html</ref><ref>http://archive.today/2022.01.04-232251/https://www.faz.net/aktuell/rhein-main/bill-melinda-gates-foundation-foerdert-biontech-aus-mainz-16372372.html</ref> |
| − | == | + | ==Official narrative== |
| − | Founded in 2008 by Turkish married scientists [[Özlem Türeci]] and [[Ugur Sahin]] and the [[Austria]]n oncologist [[Christoph Huber]], the company originally set out to develop new types of immunotherapy against cancer, modifying patients’ T cells to target cancer-specific antigens. It researches drugs based on messenger RNA (mRNA) for use as individualised cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer. | + | Founded in [[2008]] by Turkish-German married scientists [[Özlem Türeci]] and [[Ugur Sahin]] and the [[Austria]]n oncologist [[Christoph Huber]], the company originally set out to develop new types of immunotherapy against [[cancer]], modifying patients’ T cells to target cancer-specific antigens. It researches drugs based on messenger RNA (mRNA) for use as individualised cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for [[cancer]]. |
| − | BioNTech developed an mRNA-based human therapeutic for intravenous administration, to bring individualised mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process.<ref>''[https://sec.report/Document/0001193125-19-241112/ "Form F-1 BioNTech SE"]''</ref> | + | BioNTech developed an [[mRNA]]-based human therapeutic for intravenous administration, to bring individualised mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process.<ref>''[https://sec.report/Document/0001193125-19-241112/ "Form F-1 BioNTech SE"]''</ref> |
| − | ==COVID-19 vaccine== | + | ==COVID-19 "vaccine"== |
| − | The company’s shares shot up 23.4% | + | {{FA|Pfizer–BioNTech COVID-19 vaccine}} |
| + | {{SMWQ | ||
| + | |text=A year ago today, not everyone was aware that we were going to live in a pandemic. But some already knew or suspected it; and that included Mr. Şahin, the head of BioNTech, who told me that on January 24 he made the decision to overturn the entire BioNTech research program and develop an mRNA vaccine for this virus. | ||
| + | |subjects= | ||
| + | |authors=Angela Merkel | ||
| + | |date=26 Januar 2021 | ||
| + | |source_details=https://web.archive.org/web/20210128105132/https://www.bundesregierung.de/breg-de/aktuelles/rede-von-bundeskanzlerin-merkel-anlaesslich-des-davos-dialogs-des-world-economic-forum-am-26-januar-2021-videokonferenz--1844594 | ||
| + | }} | ||
| + | The company’s shares shot up 23.4% after the "[[Covid-19 vaccine]]" it is developing with the US pharma giant [[Pfizer]] became the first candidate worldwide to show positive results in phase 3 trials, the crucial final stage of testing. | ||
| + | |||
| + | In November [[2020]], ''[[The Guardian]]'' reported that the total value of BioNTech’s stock is $21.9bn (£16.6bn), more than four times that of German national carrier [[Lufthansa]]<ref>''[https://www.theguardian.com/world/2020/nov/09/biontechs-covid-vaccine-a-shot-in-the-arm-for-germanys-turkish-community "BioNTech's Covid vaccine: a shot in the arm for Germany's Turkish community"]''</ref> | ||
| + | |||
| + | ===Approved for use=== | ||
| + | On 21 December 2020, following approval by the [[UK]]'s [[MHRA]] and the US [[FDA]], the [[European Medicines Agency]] (EMA) authorised the [[Pfizer]] BioNTech [[Covid-19 vaccine]] for the [[EU]]'s nearly 448 million inhabitants. The [[EMA]] said the drug had demonstrated an efficacy of 95% and could be used in people aged 16 and over: :"Today's positive news is an important step forward in our fight against this pandemic, which has caused suffering and hardship for so many," said the EMA's executive director, [[Emer Cooke]]. "Our thorough evaluation means that we can confidently assure EU citizens of the safety and efficacy of this vaccine and that it meets necessary quality standards. However, our work does not stop here. We will continue to collect and analyse data on the safety and effectiveness of this vaccine to protect people taking the vaccine in the [[EU]]."<ref>''[https://www.bbc.co.uk/news/world-europe-55401136 "Covid: Pfizer-BioNTech vaccine approved for EU states"]''</ref> | ||
| + | |||
| + | Company founder [[Ugur Sahin]] slipped up during an interview, accidentally revealing what he really thought of the product: | ||
| + | {{SMWQ | ||
| + | |text=Yes, I would love to get vaccinated too, we just have to see that we follow the legal basics. We will have to produce over 1.3 billion doses of vaccine in the next six months, it is important that there are no staff absences and accordingly we are thinking about finding ways that legally allow us to protect our staff as well. But we have, that is still in the clarification at the moment. | ||
| + | |subjects=Covid jab,Pfizer | ||
| + | |authors= Ugur Sahin | ||
| + | |date=December 2020 | ||
| + | |source_URL=https://reitschuster.de/post/chef-impf-entwickler-laesst-sich-nicht-impfen/ | ||
| + | |description=[[BioNTech]] founder [[Ugur Sahin]] | ||
| + | }} | ||
| − | |||
{{SMWDocs}} | {{SMWDocs}} | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
Latest revision as of 07:18, 27 June 2024
 BioNTech  (Big Pharma)   | |
|---|---|
 | |
| Founder | • Christoph Huber • Ugur Sahin • Özlem Türeci |
| German biotechnology company worth billions after being selected producer of a COVID jab. | |
BioNTech is a German biotechnology company. As of 2024, the company does not have any other product but the Pfizer–BioNTech COVID-19 "vaccine" (BNT162b2). The company received 55 million USD in 2019 from the Bill & Melinda Gates-Foundation.[1][2]
Official narrative
Founded in 2008 by Turkish-German married scientists Özlem Türeci and Ugur Sahin and the Austrian oncologist Christoph Huber, the company originally set out to develop new types of immunotherapy against cancer, modifying patients’ T cells to target cancer-specific antigens. It researches drugs based on messenger RNA (mRNA) for use as individualised cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.
BioNTech developed an mRNA-based human therapeutic for intravenous administration, to bring individualised mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process.[3]
COVID-19 "vaccine"
- Full article: Pfizer–BioNTech COVID-19 vaccine
- Full article: Pfizer–BioNTech COVID-19 vaccine
“A year ago today, not everyone was aware that we were going to live in a pandemic. But some already knew or suspected it; and that included Mr. Şahin, the head of BioNTech, who told me that on January 24 he made the decision to overturn the entire BioNTech research program and develop an mRNA vaccine for this virus.”
Angela Merkel (26 Januar 2021) [4]
The company’s shares shot up 23.4% after the "Covid-19 vaccine" it is developing with the US pharma giant Pfizer became the first candidate worldwide to show positive results in phase 3 trials, the crucial final stage of testing.
In November 2020, The Guardian reported that the total value of BioNTech’s stock is $21.9bn (£16.6bn), more than four times that of German national carrier Lufthansa[5]
Approved for use
On 21 December 2020, following approval by the UK's MHRA and the US FDA, the European Medicines Agency (EMA) authorised the Pfizer BioNTech Covid-19 vaccine for the EU's nearly 448 million inhabitants. The EMA said the drug had demonstrated an efficacy of 95% and could be used in people aged 16 and over: :"Today's positive news is an important step forward in our fight against this pandemic, which has caused suffering and hardship for so many," said the EMA's executive director, Emer Cooke. "Our thorough evaluation means that we can confidently assure EU citizens of the safety and efficacy of this vaccine and that it meets necessary quality standards. However, our work does not stop here. We will continue to collect and analyse data on the safety and effectiveness of this vaccine to protect people taking the vaccine in the EU."[6]
Company founder Ugur Sahin slipped up during an interview, accidentally revealing what he really thought of the product:
“Yes, I would love to get vaccinated too, we just have to see that we follow the legal basics. We will have to produce over 1.3 billion doses of vaccine in the next six months, it is important that there are no staff absences and accordingly we are thinking about finding ways that legally allow us to protect our staff as well. But we have, that is still in the clarification at the moment.”
Ugur Sahin (December 2020) [7]
References
- ↑ http://archive.today/2021.12.30-185241/https://www.wiwo.de/unternehmen/dienstleister/biontech-einstieg-mit-50-millionen-warum-bill-gates-auf-biontech-aus-mainz-setzt/24981368.html
- ↑ http://archive.today/2022.01.04-232251/https://www.faz.net/aktuell/rhein-main/bill-melinda-gates-foundation-foerdert-biontech-aus-mainz-16372372.html
- ↑ "Form F-1 BioNTech SE"
- ↑ https://web.archive.org/web/20210128105132/https://www.bundesregierung.de/breg-de/aktuelles/rede-von-bundeskanzlerin-merkel-anlaesslich-des-davos-dialogs-des-world-economic-forum-am-26-januar-2021-videokonferenz--1844594
- ↑ "BioNTech's Covid vaccine: a shot in the arm for Germany's Turkish community"
- ↑ "Covid: Pfizer-BioNTech vaccine approved for EU states"
- ↑ https://reitschuster.de/post/chef-impf-entwickler-laesst-sich-nicht-impfen/
